IFNG and neoplasm: The in vivo tumor targeting performance of L19-IFNγ KRG (Figure 4A) and L19-mIFNγ KRG (Figure 4B) was assessed by quantitative biodistribution experiments in F9 tumor-bearing mice using radiolabeled protein preparations.